AbbVie will offer reduced prices for its medicines in Medicaid and commit $100 billion over the next decade to US research, development and capital investments, including domestic manufacturing
The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies
The agreement responds directly to President Trump’s demands that drugmakers cut costs for US patients
The deal aims to address long-standing imbalances in pharmaceutical trade while boosting investment and innovation on both sides of the Atlantic
Agreements mark a major victory in the President’s long-term pledge to lower prescription drug costs for Americans
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
The FDA is beginning rulemaking to close the “adequate provision” loophole
Subscribe To Our Newsletter & Stay Updated
